2023年4月5日

布拉沃制药公司之间的伙伴关系和G42医疗保健意味着基因组学领域的突破性进展,固体癌症确诊之前,Al-based计算过程在该地区。A + B ravo制药公司,全球领先的医疗保健,和G42医疗、卫生技术总部位于阿布扎比的先驱,已经正式合作。伙伴关系旨在改变传统的医疗生态系统在中亚、非洲和印度使用人工智能(Al)和先进的医疗技术。G42医疗亚太地区建立了几个医疗计划,包括Biogenix实验室,阿联酋第一COVID-19认证大规模吞吐量实验室——时,该地区的第一个合同研究组织临床研究和组学卓越中心,在该地区最大和最尖端的组学中心。进一步利用Al-based卫生服务的目标,改善该地区的生活质量,布拉沃医药组织和参加了一个会议致力于临床基因组学,蛋白质组学,SomaLogic共和党乌兹别克斯坦塔什干肿瘤中心。出席了会议,肿瘤学家来自不同地区医院,专家G42医疗阿布扎比,Azza阿迪博士和穆罕默德拉菲克M Zuraiqi,提供重要的见解当前医疗实践和为未来的技术突破奠定了基础。布拉沃制药公司还建立了一个参考肿瘤诊断中心与共和党人在乌兹别克斯坦塔什干肿瘤中心。建立印度大使出席了剪彩仪式的H。EShri Manish Prabhat, Director Oncology Mirza Ghalib Tillyashaykhov, and other office bearers. The partnership between Bravo Pharma and G42 Healthcare signifies ground-breaking progress in the field of genomics, pre-diagnosis of solid cancer, and Al-based computational processes, extending beyond the current scope of healthcare available in the region. The partnership will deploy best-in-class sequencing technologies and clinical genomics sequencing services along with clinical reporting and bioinformatics to drive healthcare industry advancements. Bravo Pharma CMD Rakesh Pandey, a well-known entrepreneur and social philanthropist has been the center of the company’s operations on extending the field of genomics and pre-diagnosis of solid cancer both geographically and research-wise. Regarding the collaboration, he stated, “For us, this partnership comes as a step closer to our mission of taking healthcare to the next level. As time and technology advance, we have the duty to provide everyone with the best and leading healthcare possible to ensure the highest quality of life for all. With G42 Healthcare’s AI development and our core new drug discovery cytogenetic, targeted therapy, and advanced diagnostics competencies, we will be able to spearhead the region’s genome and health data computation processes.” Kareem Shahin, Chief Business Officer, of G42 Healthcare commented, “Joining hands with Bravo Pharma strengthens our unified vision for a more personalized, intelligent, and value-based healthcare model. The impactful collaboration will enable us to deploy our best-in-class sequencing technologies to provide clinical genomics sequencing services coupled with clinical reporting and bioinformatics to propel healthcare forward.” With Bravo Pharma at the forefront of genome sequencing and advanced diagnostic equipment, and G42 Healthcare driving Al innovation, the strategic partnership that has been formed holds the potential to drastically improve the healthcare ecosystem in Central Asia, Africa, and India. About Bravo Pharma Bravo Pharma is a UK-based, global healthcare company, leading the field of genome sequencing solutions, advanced diagnostics, equipment, and research. They utilize the world’s most modern and innovative technologies in drug development, targeted therapy, and non-invasive diagnostics to deliver the utmost quality of life to all. For more information, visit https:// www.bravopharma.com/ ThePrint ValueAd Initiative content is a paid-for, sponsored article. Journalists of ThePrint are not involved in reporting or writing it. Subscribe to our channels on YouTube & Telegram Support Our Journalism India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that. Sustaining this needs support from wonderful readers like you. Whether you live in India or overseas, you can take a paid subscription by clicking here .